A high ratio of IC31(®) adjuvant to antigen is necessary for H4 TB vaccine immunomodulation

A tuberculosis (TB) vaccine consisting of a recombinant fusion protein (H4) and a novel TLR9 adjuvant (IC31) is in clinical development. To better understand the H4-IC31 ratio, we measured the binding capacity of IC31 for H4 protein and immunized mice with formulations that contained limiting to exc...

Descripción completa

Detalles Bibliográficos
Autores principales: Aboutorabian, Sepideh, Hakimi, Jalil, Boudet, Florence, Montano, Sandrine, Dookie, Annie, Roque, Cristopher, Ausar, Salvador F, Rahman, Nausheen, Brookes, Roger H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514381/
https://www.ncbi.nlm.nih.gov/pubmed/25997147
http://dx.doi.org/10.1080/21645515.2015.1023970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514381/
https://www.ncbi.nlm.nih.gov/pubmed/25997147
http://dx.doi.org/10.1080/21645515.2015.1023970

Ejemplares similares